| Angiogenesis inhibitors in the management of breast cancer. | |
| | |
MedLine Citation:
|
PMID: 19952746 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: An improved understanding of the important role of angiogenesis in tumor biology has led to development of different antiangiogenic therapies. This review highlights therapeutic agents from recent breast cancer trials showing the greatest potential for further clinical use in the near future. RECENT FINDINGS: Numerous clinical studies for several antiangiogenic agents have recently been conducted in breast cancer patients and different antiangiogenic approaches have demonstrated their antitumor activity. Bevacizumab is the most advanced agent, being the first approved angiogenesis inhibitor in metastatic breast cancer. The multikinase inhibitors sorafenib, sunitinib, and pazopanib have also shown promising early results and are further evaluated. To maximize efficacy and safety of antiangiogenic agents and help selecting patients suitable for this therapy, identification of predictive biomarkers is essential. SUMMARY: Novel antiangiogenic agents have produced positive data in clinical trials for breast cancer leading to the approval of bevacizumab for the first-line therapy of metastatic breast cancer. Other interesting substances such as multikinase inhibitors are currently being investigated. So far, angiogenesis inhibitors provide an additional therapeutic option for metastatic breast cancer; their role in early breast cancer as well as optimal patient selection will need further research. |
| | |
Authors:
|
Verena Bossung; Nadia Harbeck |
Related Documents
:
|
17591826 - Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. 10926086 - Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prosta... 15695826 - Betaiii-tubulin induces paclitaxel resistance in association with reduced effects on mi... 12849616 - Herceptin: implications for breast cancer management. 21178756 - Subcutaneous pre-expansion of mastectomy flaps before breast reconstruction with deep i... 808266 - Advances in the management of gynecologic cancer--radiation therapy. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in obstetrics & gynecology Volume: 22 ISSN: 1473-656X ISO Abbreviation: Curr. Opin. Obstet. Gynecol. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2009-12-25 Completed Date: 2010-04-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007264 Medline TA: Curr Opin Obstet Gynecol Country: England |
Other Details:
|
Languages: eng Pagination: 79-86 Citation Subset: IM |
Affiliation:
|
Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use* Breast Neoplasms / drug therapy* Female Humans Protein Kinase Inhibitors / therapeutic use Vascular Endothelial Growth Factor A / antagonists & inhibitors*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Protein Kinase Inhibitors; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical and radiologic staging of cervical cancer.
Next Document: Copy number variations and cancer susceptibility.